高危肺栓塞住院患者中的体外膜氧合与再灌注策略
该观察性流行病学分析基于美国全国住院患者样本(NIS)2016—2020年数据,纳入122,735例高危肺栓塞住院患者,评估体外膜氧合(ECMO)联合溶栓类再灌注或机械再灌注与院内死亡率和重大出血的关系。ECMO使用率为2.3%(2,805例),其中单纯ECMO 1.4%、联合溶栓类再灌注0.4%、联合机械再灌注0.5%。与既无再灌注也无ECMO相比,ECMO联合溶栓类再灌注与院内死亡率降低相关(aOR 0.61;95%CI 0.38-0.98),ECMO联合机械再灌注无差异(aOR 1.03;95%CI 0.67-1.60),单纯ECMO与死亡率升高相关(aOR 1.60;95%CI 1.22-2.10)。心脏骤停亚组中ECMO与院内死亡率降低相关(aOR 0.71;95%CI 0.53-0.93)。
要点
- 122,735例高危肺栓塞住院中ECMO使用2,805例(2.3%),单纯ECMO 1.4%、联合溶栓类再灌注0.4%、联合机械再灌注0.5%。
- 与既无再灌注也无ECMO相比,ECMO联合溶栓类再灌注与院内死亡率降低相关(aOR 0.61;95%CI 0.38-0.98)。
- 单纯ECMO与院内死亡率升高相关(aOR 1.60;95%CI 1.22-2.10),提示ECMO不宜脱离再灌注单独使用。
- 心脏骤停亚组中ECMO与院内死亡率降低相关(aOR 0.71;95%CI 0.53-0.93)。
- 全部ECMO患者中,溶栓类再灌注与死亡率降低显著相关(aOR 0.55;95%CI 0.33-0.91),机械再灌注呈降低趋势(aOR 0.75;95%CI 0.47-1.19),且未增加重大出血。
适用人群与场景
- 美国全国住院患者样本(NIS)2016—2020年收录的高危肺栓塞住院患者,共122,735例。
- 结论针对高危肺栓塞且血流动力学不稳定难以纠正的患者,作者认为ECMO可作为再灌注治疗的辅助手段。
研究设计与关键结果
- 研究设计为观察性流行病学分析,数据来自美国全国住院患者样本(NIS)2016—2020年,共纳入122,735例高危肺栓塞住院患者。
- ECMO使用2,805例(2.3%),其中单纯ECMO 1.4%、联合溶栓类再灌注(全身溶栓或导管导向溶栓)0.4%、联合机械再灌注(外科取栓或导管导向血栓清除)0.5%。
- 与既无再灌注也无ECMO相比,ECMO联合溶栓类再灌注与院内死亡率降低相关(aOR 0.61;95%CI 0.38-0.98)。
- 与既无再灌注也无ECMO相比,ECMO联合机械再灌注与院内死亡率无差异(aOR 1.03;95%CI 0.67-1.60),单纯ECMO与院内死亡率升高相关(aOR 1.60;95%CI 1.22-2.10)。
- 心脏骤停亚组中,ECMO与院内死亡率降低相关(aOR 0.71;95%CI 0.53-0.93)。
- 全部ECMO患者中,与无再灌注相比,溶栓类再灌注与院内死亡率降低显著相关(aOR 0.55;95%CI 0.33-0.91),机械再灌注呈降低趋势(aOR 0.75;95%CI 0.47-1.19),且均未增加重大出血。
证据类型、等级与局限
- 证据类型:观察性流行病学分析,基于美国全国住院患者样本(NIS)2016—2020年数据。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,对高危肺栓塞且血流动力学不稳定难以纠正的患者,ECMO可作为再灌注治疗的辅助手段,但不应作为单独治疗,尤其对发生心脏骤停的患者。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To investigate the contemporary use of extracorporeal membrane oxygenation (ECMO) in conjunction with reperfusion strategies in high-risk pulmonary embolism (PE).
DESIGN: Observational epidemiological analysis.
SETTING: The U.S. Nationwide Inpatient Sample (NIS) (years 2016-2020).
PATIENTS: High-risk PE hospitalizations.
MEASUREMENTS AND MAIN RESULTS: Use of ECMO in conjunction with thrombolysis-based reperfusion (systemic thrombolysis or catheter-directed thrombolysis) or mechanical reperfusion (surgical embolectomy or catheter-based thrombectomy) with regards to in-hospital mortality and major bleeding. We identified high-risk PE hospitalizations in the NIS (years 2016-2020) and investigated the use of ECMO in conjunction with thrombolysis-based (systemic thrombolysis or catheter-directed thrombolysis) and mechanical (surgical embolectomy or catheter-based thrombectomy) reperfusion strategies with regards to in-hospital mortality and major bleeding. Among 122,735 hospitalizations for high-risk PE, ECMO was used in 2,805 (2.3%); stand-alone in 1.4%, thrombolysis-based reperfusion in 0.4%, and mechanical reperfusion in 0.5%. Compared with neither reperfusion nor ECMO, ECMO plus thrombolysis-based reperfusion was associated with reduced in-hospital mortality (adjusted odds ratio [aOR] 0.61; 95% CI, 0.38-0.98), whereas no difference was found with ECMO plus mechanical reperfusion (aOR 1.03; 95% CI, 0.67-1.60), and ECMO stand-alone was associated with increased in-hospital mortality (aOR 1.60; 95% CI, 1.22-2.10). In the cardiac arrest subgroup, ECMO was associated with reduced in-hospital mortality (aOR 0.71; 95% CI, 0.53-0.93). Among all patients on ECMO, thrombolysis-based reperfusion was significantly associated (aOR 0.55; 95% CI, 0.33-0.91), and mechanical reperfusion showed a trend (aOR 0.75; 95% CI, 0.47-1.19) toward reduced in-hospital mortality compared with no reperfusion, without increases in major bleeding.
CONCLUSIONS: In patients with high-risk PE and refractory hemodynamic instability, ECMO may be a valuable supportive treatment in conjunction with reperfusion treatment but not as a stand-alone treatment especially for patients suffering from cardiac arrest.
参考来源
- Farmakis IT, Sagoschen I, Barco S, et al. Extracorporeal Membrane Oxygenation and Reperfusion Strategies in High-Risk Pulmonary Embolism Hospitalizations. Crit Care Med. 2024. PMID: 38904439. doi:10.1097/CCM.0000000000006361
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。